Netherlands· NL-4de39372db57
Metalyse 10.000 units, poeder en oplosmiddel voor oplossing voor injectie
A tenecteplase product containing tenecteplase, registered in Netherlands by Boehringer Ingelheim International GmbH. The same ATC class is registered in 13 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Tenecteplase is registered in 13 of 19 countries.
Countries holding a registration under ATC B01AD11 (tenecteplase), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Tenecteplase · ATC B01AD11
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of tenecteplase costs, country by country.
Normalised to the WHO defined daily dose (40 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tenecteplase · price per daily dose (40 mg)
USD · FX 28 Sept 2026
- CZ Czechia$131.27
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- TENECTEPLASE
- Manufacturer
- Boehringer Ingelheim International GmbH
- Country
- Netherlands (NL)
- ATC code
- B01AD11
- ATC class
- Tenecteplase
- Defined daily dose
- 40 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/00/169
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
143 interactions on record for tenecteplase.
Graded by severity as the source publishes them — 49 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tenecteplase · interactions on record
143 records
- 49 severe
- 94 moderate
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- DalteparinB01AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Tenecteplase in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandMetalyseBoehringer Ingelheim International GmbH
- BelgiumMetalyse 10000 UBoehringer Ingelheim International
- SpainMETALYSE 10.000 UNIDADES (50 MG) POLVO Y DISOLVENTE PARA SOLUCION INYECTABLEBoehringer Ingelheim International Gmbh
- SwedenMetalyse 10 000 enheter Pulver och vätska till injektionsvätska, lösningBoehringer Ingelheim International GmbH
- CzechiaMETALYSEBoehringer Ingelheim International GmbH, Ingelheim am Rhein
- United KingdomMetalyse 10,000unit powder and solvent for solution for injection vialsBoehringer Ingelheim Ltd
- IrelandMetalyse 10 000 units (50 mg) powder and solvent for solution for injectionBoehringer Ingelheim International GmbH
- IcelandMetalyseBoehringer Ingelheim International GmbH*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Metalyse
- Liechtenstein · Metalyse
- Norway · Metalyse
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/702b9403-b2f2-4565-9cb2-416edf8c3078 GET /v1/drugs/702b9403-b2f2-4565-9cb2-416edf8c3078?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Poeder en oplosmiddel voor oplossing voor injectie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/metalyse-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Tenecteplase",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp70807",
"excipients": [
"ARGININE, (L-)",
"FOSFORZUUR (E 338)",
"POLYSORBAAT 20 (E 432)",
"STIKSTOF (HEAD SPACE) (E 941)",
"WATER VOOR INJECTIE"
],
"substances": [
"TENECTEPLASE"
],
"leaflet_url": null,
"authorised_at": "2001/02/23",
"procedure_number": "EMEA/H/C/000306",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/00/169",
"additional_monitoring": "N"
}See everything about tenecteplase.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.